Investigating how antibodies can enhance cancer treatment by targeting specific immune signals.
Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis
This study is looking at how certain parts of our immune system can help make cancer treatments work better, especially for patients who haven't had success with current therapies.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10911922 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Fc receptors in the effectiveness of antibodies that target the CD47-SIRP-alpha axis, which is crucial for enhancing the immune system's ability to fight cancer. The principal investigator, a Medical Oncology Fellow, will work under the guidance of a leading expert in the field, developing new skills in antibody and tumor biology. The study aims to identify mechanisms that improve responses to cancer immunotherapies, potentially leading to more effective treatments for patients who currently do not respond to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may be resistant to current immunotherapy treatments.
Not a fit: Patients with cancers that are already effectively treated by existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the immune response, benefiting patients who have limited options.
How similar studies have performed: Previous research has shown promising results in enhancing cancer treatment through similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Osorio, Juan C — Sloan-Kettering Inst Can Research
- Study coordinator: Osorio, Juan C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.